Renal effects of amlodipine in normotensive patients, this does not resolve following withdrawal of CsA [3]. renal transplant recipients. The use of cyclosporin A (CsA) has improved the success of renal transplanta-It has been suggested that the vasodilator action of calcium channel blockers may be useful in opposing tion, but is associated with hypertension and significant renal toxicity. Previous reports suggest that calcium the vasoconstrictor effects of CsA in renal transplant patients [4,5], and these agents have been reported to channel blockers may be useful in opposing the adverse effects of CsA. We have evaluated the effects of amlodi-protect renal function in both the short and the long term [6 ]. Recent studies have indicated that the long-pine (5 mg, once daily for 8 weeks) on renal function in 27 normotensive renal transplant recipients with acting calcium channel blocker amlodipine improves allograft function in renal transplant patients more stable renal function, in a double-blind, placebocontrolled, multicentre, cross over study. Amlodipine effectively than placebo, or angiotensin converting enzyme (ACE ) inhibitors, which have been evaluated significantly reduced serum creatinine concentration relative to placebo (mean±SD: 168±65 vs 177± as another potentially useful vasodilator therapy in these patients [7,8]. 66 mmol/l; P=0.002) and there was a strong trend towards an increase in effective renal plasma flow on Some calcium channel blockers, including the dihydropyridine nicardipine, may increase blood CsA con-amlodipine relative to placebo (238±92 vs 217±87 ml/min; P=0.055). Glomerular filtration rate and centrations through competitive inhibition of CsA metabolism at the level of cytochrome P-450 [9-13], lithium clearance were unaffected. Trough CsA blood concentration was unaffected. Amlodipine was well thereby increasing the risk of renal toxicity. Thus, the actions of calcium channel blockers in patients with tolerated, with a low incidence of adverse events, and did not affect blood pressure or heart rate. In conclu-renal impairment are heterogenous, complex, and require further investigation. The aim of the present sion, amlodipine reduced serum creatinine in normotensive renal transplant recipients after only 8 weeks study was to study the effects of amlodipine on graft function in CsA treated normotensive renal transplant treatment, and was well tolerated in concomitant administration with CsA.
Introduction
This was a multicentre, double-blind, two-way, cross over study to investigate the effects of amlodipine on renal function in normotensive, post-renal transplant patients with Immunosuppressive therapy with cyclosporin A (CsA) mild renal insufficiency during CsA treatment. Following a greatly enhances long term survival of allografts in 12-week placebo run-in, patients were randomized into two renal transplant patients [1] . The use of CsA following treatment groups. The first active treatment period involved transplantation is also associated with vasoconstricadministration of either amlodipine or placebo; patients were tion, particularly in the renal vasculature [2] . As a then crossed over on to the alternative treatment for a further result, between 20 and 95% of patients develop hyper-8 weeks with no intervening washout period. tension, with a high proportion of patients also developing some degree of renal impairment. In 5-15% of Patients transplant at least 3 months previously. Patients were normo-a parametric analysis of variance appropriate to a twotreatment cross over trial [14] . tensive, defined as supine diastolic blood pressure (DBP) between 75 and 95 mmHg. Although renal function was impaired (serum creatinine between 2 and 7 mmol/l/kg body weight), this was stable for at least 12 weeks prior to Results randomization and patients were on a stable dose of CsA for at least 2 months prior to enrolment into the study. All Demographics patients gave informed consent.
Criteria for exclusion from the study included: patients Patients were allocated in equal numbers to receive either who had received any drug within the previous 3 months amlodipine or placebo as the first treatment ( Table 1) . The which may have interfered with study medication; clinically characteristics of patients in each treatment group were significant concomitant disease; significant haematological or generally well matched. The ratio of males to females and biochemical findings (apart from those associated with renal body weight were very similar in each group, though the insufficiency); acute rejection of renal allograft within the group which received placebo before amlodipine was slightly last 3 months. younger, and tended to have a longer duration of renal insufficiency, a longer time since transplant, lower serum Treatments creatinine, and a lower daily CsA dose. Of the 30 patients originally allocated to treatment groups, three patients did Throughout the 12-week run-in period and during the treatnot receive both treatments and were not included in the ment phase of the study, patients were given encapsulated final analysis. The safety analysis included 29 patients who CsA (SandimmunB) to ensure standardization of dosing. In received placebo and 28 patients who received amlodipine. addition to CsA, patients received other immunosuppressive A total of 19 patients had concomitant conditions at medication (azathioprine and prednisolone), which they were screening, the most common of which were essential hyperasked to take at regular times and at constant dosage tension in four patients (though these patients fulfilled the throughout the study. During each 8-week active treatment entry criterion of DBP <95 mmHg), duodenal ulcers in phase, amlodipine (5 mg) or matching placebo were administhree patients and oedema in three patients. Concomitant tered orally once daily. medications were recorded in 27 patients at screening, the most common of which were frusemide (nine patients), nifedipine (eight patients), and ranitidine (eight patients).
Assessments
One patient continued to receive nifedipine. All patients were receiving CsA at screening, and in some cases were also Serum concentrations of creatinine, urea and electrolytes taking azathioprine (12 patients) and prednisolone (16 were measured in venous blood samples at each visit during patients). The distributions of concomitant conditions and the 12-week run-in and at the end of each treatment period. therapies were similar for the two-treatment groups. Lithium clearance, glomerular filtration rate (GFR; by plasma clearance of Tc-99m labelled DTPA), and effective renal plasma flow ( ERPF; by plasma clearance of 125I-Effects on renal function and CsA concentrations labelled hippuran) were measured at the end of the run-in period and following both treatment periods.
The effects of amlodipine on renal function are shown in Whole blood trough CsA concentrations were measured Table 2 . Serum creatinine remained similar to baseline during (using a radioimmunoassay method ) on samples taken immeplacebo administration, whereas this parameter was reduced diately before oral administration of CsA. significantly during amlodipine treatment. In addition, there Adverse events noted during treatment were recorded and was a strong trend for ERPF to increase during amlodipine designated as 'drug related', 'possibly drug related', or 'not treatment and to decrease during placebo treatment. The drug related'. The onset date, duration and severity (mild, difference between the treatments almost achieved statistical moderate, or severe), and outcome were noted. The physician significance (P=0.055). Lithium clearance and GFR were made an overall assessment of adverse effects at the end of not significantly affected by amlodipine, compared to each treatment period. A range of standard haematological placebo. and biochemical measurements were carried out at baseline Trough CsA concentration, defined as the concentration and following each treatment period. Body weight and vital immediately before the next dose, was unaffected by amlodipsigns (heart rate and blood pressure, using an automated ine (Table 2) . sphygmomanometer) were measured at each study visit, with vital signs also monitored 6 h after the CsA dose at baseline and after each treatment period.
Tolerability
Adverse events, considered to be possibly related to treat-Statistics ment, were reported by four patients receiving placebo, and consisted of 'mild' epistaxis, postural dizziness, leg cramps, An estimated sample size of 24 patients was required to detect a difference in creatinine concentration of 30 mmol/l and 'moderate' worsening of gout. Two patients receiving amlodipine reported treatment-related adverse events, between treatments, with a power of 80% and a significance level of P=0.05 (two-tailed ), assuming a within patient described as 'mild' worsening of oedema together with 'severe' epistaxis in one patient, and 'moderate' leg oedema, standard deviation of treatment difference of 50 mmol/l. Data from all patients with measurements in both the placebo and leading to withdrawal of treatment, in the other. There were no major shifts in laboratory or haematological variables amlodipine treatment periods were included in analysis. No period effects were found in the data, therefore data from during placebo or amlodipine. In the overall evaluation of tolerability, amlodipine was considered to be well tolerated both treatment sequences were analysed as a whole. Differences in means between treatments were explored using with a low incidence of adverse effects. Haemodynamics this parameter in renal transplant patients following treatment for up to 1 year [15-17]. The improvement The effects of amlodipine on BP and heart rate are shown in creatinine was not associated with a rise in GFR; in Table 3 . Mean SBP fell slightly during treatment with this could be due either to a type II error (related to placebo and amlodipine, by 6 and 8 mmHg, respectively. small numbers) or alternatively, to a pharmacological DBP was essentially unchanged on placebo and fell by an reduction in tubular reabsorption of creatinine or an average of 4 mmHg on amlodipine. These changes were not increase in tubular secretion of creatinine (by amlodipstatistically significant between treatments. Heart rate was ine). However, this was not evaluated during this study unaffected by amlodipine. and warrants further investigation.
However, several studies have demonstrated improvements in other indices of renal function in CsA Discussion treated transplant patients following treatment with amlodipine and other calcium channel blockers The purpose of this double-blind, placebo-controlled, [4, 7, 8, [17] [18] [19] [20] . The degree of renal protection afforded cross over study was to evaluate the effects of amlodipby amlodipine compares favourably with that of ACE ine in renal transplant patients with impaired renal inhibitors. In one study, 8 weeks of treatment with function, but without hypertension. Amlodipine was amlodipine was more effective than ACE inhibition well tolerated, with a low incidence of adverse effects.
with perindopril in increasing lithium and urate clear-The significant reduction in serum creatinine (P= ance [8] . A further study showed that 4 weeks treat-0.002) and the tendency towards an increase in ERPF ment with amlodipine, but not with the ACE inhibitor (P=0.055) indicated an improvement in renal function lisinopril, increased GFR and ERPF, and reduced during amlodipine treatment. Such an improvement in renal vascular resistance [7]. serum creatinine, after only 8 weeks treatment of In assessing the renal protective effects of calcium patients with stable renal impairment, contrasts with channel blockers, it is difficult to separate direct effects other studies, which have failed to demonstrate a significant effect of other calcium channel blockers on on the kidney from benefits resulting from indirect haemodynamic effects [21] . Most previous reports of treatment. Amlodipine was well tolerated in these normotensive patients, and has well documented effi-the renal effects of amlodipine are from studies in hypertensive renal transplant patients [5, 7, 8] or hyper-cacy in hypertension. The long duration of action of amlodipine, with relatively stable blood levels over tensive patients with diabetic nephropathy [22] . The effects of vasodilator treatments on renal function in time, contributes to its suitability for concomitant administration with CsA. these patients do not consistently parallel their haemodynamic effects, suggesting that other protective mechanisms may be involved. For example, the reduction References in proteinuria by amlodipine in diabetic nephropathy is comparable to that of ACE inhibitors, but is superior 1. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its to that of nifedipine, despite the potent antihypertenspharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: ive effects of all three therapies in these patients 953-1040 [23] [24] [25] [26] [27] [28] . Furthermore, the beneficial renal effects of interactions would therefore be of value. However, [1227] [1228] [1229] [1230] [1231] there is at present insufficient evidence from this and 17. Vasquez EM, Pollak R. Effect of calcium channel blockers on other studies, in which drugs were given by the oral graft outcome in cyclosporin treated renal allograft recipients. route, to support an interaction between amlodipine 
